Dr Castillo publishes an editorial on LOHN therapeutic perspectives in the journal Archivos de la Sociedad Española de Oftalmología

Medical content revised by - Last revision 03/04/2017
Dr Castillo publishes an editorial on LOHN therapeutic perspectives in the journal Archivos de la Sociedad Española de Oftalmología

An editorial on LOHN therapeutic perspectives (Leber’s Hereditary Optic Neuropathy) from Dr Lorena Castillo, Head of Neuro-Ophthalmology Department at ICR, has been published in the December issue of the journal Archivos de la Sociedad Española de Oftalmología.

Editorials in medical journals are published by leading specialists in a specific area, and are aimed at analyzing and synthetizing the scientific evidence on the mentioned area, in this case LOHN disease, and give an opinion on common perspectives. Dr Castillo is a national expert on this medical area and works as a consultant and member of ASANOL’s (Leber’s Optic Nerve Atrophy Association) Scientific Committee, a non-profit association whose aim is to make known, research and report on this low prevalence disease that causes a significant and sudden loss of vision in considerably young patients.

Idebenone, gene therapy and LOHN therapeutic perspectives

LOHN (Leber’s Hereditary Optic Neuropathy) is a disease that generally causes a sever vision loss in both eyes, and it is the most common hereditary optic neuropathy. Its cause is a mitochondrial mutation (in the mitochondrial DNA inherited only from the mother).

Dr Castillo’s editorial addresses the different treatment options for the disease, and especially, the use of two therapeutic pathways. The first one is the use of idebenone, a benzoquinone, synthetic analogous to coenzyme Q10 which has a preventive effect on the oxidative action of reactive oxygen species to mitochondria. Idebenone (Raxone®, Santhera Pharmaceuticals) is, nowadays, the only approved treatment for LOHN. Dr Castillo takes part as principal investigator in the phase-4 clinical trial aiming to assess the efficiency and security in the long run of the use of idebenone in patients affected by LOHN.

The second pathway addresses the gene therapy as a possible treatment for the disease. It consists in the introduction of absent functional elements in human genome which is performed on cells and tissues. It is aimed at treating diseases and is no longer the future, but an emerging reality. Currently, from 5 clinical trials being carried out globally on this disease, two of them are already at phase 3. In this sense, Dr Castillo collaborates with GenSight Biologics, a biotechnology company responsible for the 2 gene therapy trials currently at phase 3, with the aim of making them accessible to Spanish patients, so they can be possible candidates.

Online consultation of Dr Castillo’s editorial

Elsevier has published in Science Direct the complete version of Dr Castillo’s editorial on LOHN treatment, in an English version that can be freely accessed until January 19th, 2017.

Post your comment

In accordance with the provisions of the General Data Protection Regulation (REGULATION (EU) 2016/679), the following information about the processing of personal data is disclosed to you.

Responsible: Institut Català de la Retina, S.L., Institut Català de Cirurgia refractiva, S.L. (from now on ICR)

Representative of Data Protection Contact: C/Pau Alcover nº 67 08017 Barcelona – rgpd@icrcat.com

Aim: The purpose of the treatment is to manage the information you provide us and after having your consent, publish the testimonial on our website.

Legitimization: The legal basis for the present treatment is the request made by you and having your consent.

Recipients: The recipients of the information are the departments and delegations in which ICR is organized, in part or in its entirety. It will not be communicated to third parties.

Rights: At any time, you can exercise your rights of access, rectification, deletion, opposition, limitation of treatment and / or portability of data by writing to the RPD Representative of Data Protection at the address provided in contact. You can also revoke consents to other treatments. You can also request more information from the RPD about the treatments performed.
In the event that you consider that your rights have been violated, you can submit a claim to the competent Data Protection Control Authority.

For all purposes, the user accepts that the opinion expressed will be exclusively his /her responsibility. The user assumes under his / her exclusive responsibility the damages or harms that may derive from it.
ICR will not be responsible for the accuracy, quality, reliability, correctness, morality and legality of the data, information or opinions published by users.
ICR reserves the right not to publish all opinions of users.
The user is solely responsible of his /her username. ICR will not be responsible for the illegal use or for illicit purposes that other users can make of this user name.

Preservation: The collected data will be kept during the time required for the requested management, for at most 30 days.

ICR Ganduxer Headquarters

c/Ganduxer,117
08022 Barcelona

ICR Pau Alcover

C. Pau Alcover 67
08017 Barcelona

ICR Terrassa

C. del Nord, 77
08221 Terrassa

Clínica Bonanova Surgical Center

Passeig Bonanova, 22
08022 Barcelona

Clinica Bonanova Tests and Treatments

c/ Mandri, 63
08022 Barcelona

ICR Service at Clínica Ntra. Sra. del Remei

c/ de l'Escorial,148
08024 Barcelona
This website uses cookies in order to collect statistical information regarding navigation. If you keep on surfing this website, it shall be deemed to have acknowledged its use. More information.